These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 17659471)

  • 1. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside.
    Arbel M; Solomon B
    Trends Immunol; 2007 Dec; 28(12):511-3. PubMed ID: 17981084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.
    Lord A; Gumucio A; Englund H; Sehlin D; Sundquist VS; Söderberg L; Möller C; Gellerfors P; Lannfelt L; Pettersson FE; Nilsson LN
    Neurobiol Dis; 2009 Dec; 36(3):425-34. PubMed ID: 19703562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immune system, amyloid-beta peptide, and Alzheimer's disease.
    Weksler ME; Gouras G; Relkin NR; Szabo P
    Immunol Rev; 2005 Jun; 205():244-56. PubMed ID: 15882358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
    Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
    J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress in beta-amyloid immunotherapy.
    Schenk D; Hagen M; Seubert P
    Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
    Morgan D; Gitter BD
    Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
    Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome.
    Oddo S; Billings L; Kesslak JP; Cribbs DH; LaFerla FM
    Neuron; 2004 Aug; 43(3):321-32. PubMed ID: 15294141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination.
    Solomon B
    Vaccine; 2005 Mar; 23(17-18):2327-30. PubMed ID: 15755621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease.
    Wang CY; Finstad CL; Walfield AM; Sia C; Sokoll KK; Chang TY; Fang XD; Hung CH; Hutter-Paier B; Windisch M
    Vaccine; 2007 Apr; 25(16):3041-52. PubMed ID: 17287052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's disease.
    McGeer PL; McGeer E
    Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
    Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
    Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.
    Wang YJ; Pollard A; Zhong JH; Dong XY; Wu XB; Zhou HD; Zhou XF
    Neurobiol Aging; 2009 Mar; 30(3):364-76. PubMed ID: 17686552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.